Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
12.10B
Market cap12.10B
Price-Earnings ratio
-28.25
Price-Earnings ratio-28.25
Dividend yield
Dividend yield
Average volume
2.29M
Average volume2.29M
High today
$73.61
High today$73.61
Low today
$69.63
Low today$69.63
Open price
$70.68
Open price$70.68
Volume
1.69M
Volume1.69M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$23.95
52 Week low$23.95

Stock Snapshot

The current Ionis Pharmaceuticals(IONS) stock price is $73.25, with a market capitalization of 12.1B. The stock trades at a price-to-earnings (P/E) ratio of -28.25.

On 2026-03-25, Ionis Pharmaceuticals(IONS) stock traded between a low of $69.63 and a high of $73.61. Shares are currently priced at $73.25, which is +5.2% above the low and -0.5% below the high.

The Ionis Pharmaceuticals(IONS)'s current trading volume is 1.69M, compared to an average daily volume of 2.29M.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $23.95 at its lowest and $86.74 at its peak.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $23.95 at its lowest and $86.74 at its peak.

IONS News

TipRanks 3h
Ionis Pharmaceuticals price target raised to $83 from $77 at Stifel

Stifel analyst Paul Matteis raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $83 from $77 and keeps a Hold rating on the shares after the compa...

Nasdaq 2d
Ionis: FDA Accepts For Priority Review NDA For Zilganersen

(RTTNews) - Ionis Pharmaceuticals (IONS) announced that the FDA has accepted for Priority Review the New Drug Application for zilganersen, an investigational RN...

Ionis: FDA Accepts For Priority Review NDA For Zilganersen
TipRanks 2d
Ionis announces NDA for zilganersen accepted by U.S. FDA for Priority Review

Ionis Pharmaceuticals (IONS) announced that the U.S. Food and Drug Administration, FDA, has accepted for Priority Review the New Drug Application, NDA, for zilg...

Analyst ratings

77%

of 22 ratings
Buy
77.3%
Hold
22.7%
Sell
0%

More IONS News

Simply Wall St 7d
Did Ionis Pharmaceuticals' Board Refresh and Return of Peter Reikes Just Shift Its Investment Narrative?

Ionis Pharmaceuticals recently announced that long-serving directors B. Lynne Parshall and Joseph Wender will retire from its board in June 2026, with former di...

Did Ionis Pharmaceuticals' Board Refresh and Return of Peter Reikes Just Shift Its Investment Narrative?

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.